Dr. Loren K. Mell, MD

Dr. Mell practices at UCSD Hillcrest Medical Center in San Diego, California.

Dr. Mell's NPI, 1316119704, was assigned on March 26, 2008. Dr. Mell graduated from Pritzker School of Medicine in 2003. Dr. Mell holds California license A104704.

Dr. Mell's primary practice is UCSD Hillcrest Medical Center, at 200 W Arbor Dr, San Diego, CA 92103 in San Diego County. The practice phone is (619) 543-6222.

Dr. Mell's primary practice is UCSD Hillcrest Medical Center in San Diego, California. Dr. Mell is also affiliated with Hillcrest Medical Center. The medical group on file is UC San Diego Health. Dmand AI also links Dr. Mell to 3 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Mell practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Mell's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Mell is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Mell's licenses on file in 2 states: California and Illinois.

Dmand AI lists bladder cancer radiation, breast cancer radiation and head & neck cancer radiation among the conditions Dr. Mell treats.

CMS data shows 1,533 Medicare services from Dr. Mell across 19 procedure codes in 2024, for 225 Medicare patients. Medicare paid $134,861 for them.

CMS counts 225 Medicare patients who saw Dr. Mell in 2024. The largest group is 65 to 74, with 109 patients. 71% of them have high blood pressure, and 68% have high cholesterol. 28% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Mell's median patient age at 65, with 46% women.

In 2024, Dr. Mell wrote 98 Medicare Part D claims for 50 patients. 91% of them were for generic drugs. CMS names the drug for 77 of them, across 3 drugs with 11 or more claims each, at $3,415 in total drug cost. In 2023, CMS named 45 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Mell for performance year 2024, reported as part of a group. Dr. Mell accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Mell as offering telehealth.

Dmand AI links 209 papers to Dr. Mell, published from 2006 to 2025. 2021 was the busiest year, with 19. The most frequent topics are Head and Neck Neoplasms, Uterine Cervical Neoplasms and Radiotherapy, Intensity-Modulated. Dr. Mell has published most often in Int J Radiat Oncol Biol Phys. Dr. Mell's most frequent co-authors are Catheryn M. Yashar, MD, Brent Shane Rose, MD and Quynh-Thu Xuan Le, MD.

Dmand AI links Dr. Mell to 18 clinical trials, 6 of them phase 2 studies. 11 are still active or recruiting. Conditions studied include Hypopharyngeal Neoplasms, Prostatic Neoplasms and Uterine Cervical Neoplasms. National Cancer Institute (NCI) sponsors the most, 5.

CMS Open Payments shows 84 general payments to Dr. Mell from 10 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 48% of the total. Varian Medical Systems, Inc. paid the most, $16,033.

Dr. Mell graduated from Pritzker School of Medicine in 2003. Dr. Mell is a member of ASCO.

Dr. Mell is in network with 16 carriers, including Aetna, Elevance and United Healthcare. PPO plans come from the most carriers, 11. Check the plan with the practice before a visit.